Dallas-based biotech startup Colossal has raised hundreds of millions from venture capitalists, the CIA, and Peter Thiel to resurrect extinct animals. The company's approach uses genetic engineering rather than cloning ancient DNA.
Colossal's ambitions span woolly mammoths, Tasmanian tigers, and dire wolves—though the marketing term "de-extinction" oversimplifies the science. The startup doesn't recover lost creatures from fossilized DNA. Instead, it modifies living animals' genomes to recreate extinct species' traits.
The 2025 dire wolf reveal exemplified this strategy: the presented animals were gray wolves with edited genes, not recreated dire wolves. This genetic approach sidesteps technical barriers that make true cloning from ancient DNA impractical.
The venture has attracted serious backing, signaling investor confidence in synthetic biology applications. However, the gap between genetic modification and true species resurrection remains substantial. Colossal's work advances biotechnology capabilities while raising questions about ecosystem integration and project timelines.
The startup represents a growing sector betting that genetic engineering can solve extinction—even if the science differs sharply from popular perception.
InstaLILY, an enterprise automation startup, has raised $60 million in Series B funding led by Energize Capital, bringing its total funding to nearly $100 million.
Adapter, an infrastructure platform enabling AI agents and applications to leverage and control data, has emerged from stealth with $17.8 million in funding led by GV.
Chinese AI developer DeepSeek is raising approximately $1.5 billion at a $71 billion valuation and planning to go public in 2027, according to reports.
State Affairs, backed by Founders Fund, launched a Bloomberg Terminal-like product that uses AI trained on reporting from its 76 staffers to deliver policy and political intelligence.